L-carnosine,
does it really help with Improved depressive symptoms and remission when added to an SSRI in major depressive disorder?
research showsL-carnosine is rated C as an SSRI adjunct for major depressive disorder. Direct evidence is one double-blind randomized trial in 58 patients comparing L-carnosine 400 mg twice daily with placebo for six weeks while both groups received citalopram. The HAM-D time-by-treatment interaction (F=3.17, p=0.03), response (p=0.023), and remission (p=0.012) were genuinely positive, providing a credible small human signal. Only 52 participants completed the short trial, however, its outcomes were subjective, and no independent replication exists, placing it in the low C range with 45 points. A 2026 review rated mood and depression evidence low in strength and quality-of-life and brain-structure outcomes very low.
ads claimMarketing converts antioxidant, antiglycation, and neurotransmitter mechanisms into claims that L-carnosine reliably accelerates SSRI response and produces remission. The MDD-specific evidence is one 58-person six-week citalopram-adjunct trial and does not test replacement of an antidepressant with a supplement.
Useful facts when choosing a product
- The pivotal trial used L-carnosine 400 mg twice daily, totaling 800 mg/day, while every participant also received citalopram.
- Carnosine is a beta-alanine and L-histidine dipeptide; beta-alanine, anserine, and zinc-L-carnosine are not the same intervention.
- The six-week trial detected no difference in adverse-event frequency from placebo, but its small sample cannot define long-term or rare harms; gastrointestinal symptoms such as nausea or constipation can occur.
- Antidepressant treatment should not be reduced or replaced without clinical advice, and the treatment team should know the complete list of supplements and prescription medicines.
What the research actually shows
Araminia and colleagues randomized 58 patients meeting DSM-5 MDD criteria with HAM-D scores of at least 19 to six weeks of L-carnosine 800 mg/day or placebo added to citalopram up to 40 mg/day. Fifty-two completed the trial; the HAM-D time-by-treatment interaction (F=3.17, p=0.03), response (p=0.023), and remission (p=0.012) favored L-carnosine, without a detected difference in adverse-event frequency. The 2025 Kabthymer meta-analysis combined 18 trials and 776 participants and found a depression-score benefit, but interventions included anserine/carnosine, L-carnosine, and beta-alanine across varied populations. The 2026 Hsiao review confirmed that Araminia remains the only direct MDD trial and rated mood and depression evidence low in strength, while quality-of-life and brain-structure outcomes were rated very low.
Why this is classified as C (45)
A direct MDD trial with a genuinely positive HAM-D time-by-treatment interaction (F=3.17, p=0.03), response (p=0.023), and remission (p=0.012) provides a credible human signal supporting C. The evidence is limited to 58 randomized participants, six weeks, 52 completers, subjective outcomes, and one research group. The pooled positive estimate mixes other histidine-containing dipeptides and non-MDD populations and is not indication-specific replication. Absent independent replication, the result belongs in the low C range with 45 points.
Counterpoint. Anyone considering it should keep prescribed treatment unchanged and discuss the supplement with the treating mental-health clinician. Suicidal thoughts, rapid worsening, or possible manic symptoms require prompt professional assessment rather than a supplement experiment.
Rejudgment record. Cross-check applied — Treated the HAM-D time-by-treatment interaction of F=3.17 and p=0.03, response at p=0.023, and remission at p=0.012 in the 58-person six-week double-blind citalopram-adjunct trial as a credible positive human signal, while 52 completers, subjective outcomes, a single study, and no independent multicenter replication place the rating in the low C range at 45
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improvement in depressive symptoms as an SSRI adjunct | C | HAM-D improved in a 58-person six-week citalopram-adjunct trial, but independent replication is absent. |
| Improvement in treatment response as an SSRI adjunct | C | Only one trial reported a positive response-rate result at p=0.023, with a small sample and event count. |
| Improvement in remission as an SSRI adjunct | C | A remission signal at p=0.012 exists, but it comes from one six-week trial with no durable-remission data. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Araminia et al. 2020 | Randomized double-blind placebo-controlled citalopram-adjunct trial | 52 | Government and academic support | Six-week HAM-D change, response, remission, and adverse events | L-carnosine 800 mg/day improved HAM-D, response, and remission versus adjunctive placebo, with no detected difference in adverse-event frequency. | Only direct positive MDD trial; small and short |
| Kabthymer et al. 2025 | Systematic review and meta-analysis of histidine-containing dipeptide randomized trials | 776 | Academic research | Depression scores and quality of life | The pooled depression effect was positive, but interventions mixed anserine/carnosine, L-carnosine, and beta-alanine across multiple populations. | Indirect synthesis with ingredient and indication heterogeneity |
| Hsiao et al. 2026 | Systematic review and meta-analysis of carnosine for cognition and mental health | 1 | Academic evidence-synthesis research | Cognition, mood and depression, quality of life, and brain function | Araminia remained the only direct MDD trial; strength of evidence was low for mood and depression and very low for quality-of-life and brain-structure outcomes. | Latest indication boundary and confirmation of absent replication |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] L-carnosine x improved depressive symptoms and remission as an SSRI adjunct in major depressive disorder — Evidence Grade C·45. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/mood/l-carnosine-ssri-adjunct-major-depressive-disorder/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.